Treatment and prevention of abnormal scarring in keloids and other internal or skin lesions or injuries

摘要

"TREATMENT AND PREVENTION OF ANORMAL SCAR FORMATION IN KELOIDS AND OTHER INJURY OR CUTANE INJURY". The present invention relates to findings that reduction of Plasminogen Activator inhibitor -1 (PAI-1) activity suppresses excessive collagen deposition which is known to cause abnormal scarring. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, disfiguring skin conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by excessive collagen deposition in a process. wound scars. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease excessive collagen accumulation. PAI-1 activity may be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine-based compounds, tetramic acid-based compounds, Vitamin C, Vitamin E, Mifepristone (RU486) and Spironolactone to name a few. Another aspect of the present invention is directed to methods of assessing PAI-1 activity in a wound healing process and determining the propensity for abnormal scar formation.